4.7 Review

Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations JACC State-of-the-Art Review

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 76, Issue 24, Pages 2878-2894

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2020.10.020

Keywords

cardiopulmonary disease; cardiovascular disease; fine particulate air pollution; portable air cleaner; randomized clinical trials

Ask authors/readers for more resources

Fine particulate air pollution <2.5 mu m in diameter (PM2.5) is a major environmental threat to global public health. Multiple national and international medical and governmental organizations have recognized PM2.5 as a risk factor for cardiopulmonary diseases. A growing body of evidence indicates that several personal-level approaches that reduce exposures to PM2.5 can lead to improvements in health endpoints. Novel and forward-thinking strategies including randomized clinical trials are important to validate key aspects (e.g., feasibility, efficacy, health benefits, risks, burden, costs) of the various protective interventions, in particular among real-world susceptible and vulnerable populations. This paper summarizes the discussions and conclusions from an expert workshop, Reducing the Cardiopulmonary Impact of Particulate Matter Air Pollution in High Risk Populations, held on May 29 to 30, 2019, and convened by the National Institutes of Health, the U.S. Environmental Protection Agency, and the U.S. Centers for Disease Control and Prevention. (C) 2020 the American College of Cardiology Foundation. Published by Elsevier. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available